Cidara Therapeutics (CDTX) Competitors $21.58 +0.75 (+3.60%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$21.69 +0.11 (+0.51%) As of 03/27/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. ABUS, SANA, CDXC, KALV, MGTX, PHAR, ARVN, RLAY, IMTX, and KURAShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), MeiraGTx (MGTX), Pharming Group (PHAR), Arvinas (ARVN), Relay Therapeutics (RLAY), Immatics (IMTX), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Arbutus Biopharma Sana Biotechnology ChromaDex KalVista Pharmaceuticals MeiraGTx Pharming Group Arvinas Relay Therapeutics Immatics Kura Oncology Arbutus Biopharma (NASDAQ:ABUS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends. Which has better valuation & earnings, ABUS or CDTX? Cidara Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.74M91.91-$72.85M-$0.43-7.60Cidara Therapeutics$1.28M185.38-$22.93M-$30.09-0.72 Does the MarketBeat Community prefer ABUS or CDTX? Cidara Therapeutics received 20 more outperform votes than Arbutus Biopharma when rated by MarketBeat users. However, 70.73% of users gave Arbutus Biopharma an outperform vote while only 70.43% of users gave Cidara Therapeutics an outperform vote. CompanyUnderperformOutperformArbutus BiopharmaOutperform Votes43570.73% Underperform Votes18029.27% Cidara TherapeuticsOutperform Votes45570.43% Underperform Votes19129.57% Do institutionals and insiders hold more shares of ABUS or CDTX? 43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ABUS or CDTX more profitable? Cidara Therapeutics has a net margin of -289.05% compared to Arbutus Biopharma's net margin of -1,137.65%. Arbutus Biopharma's return on equity of -68.18% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-1,137.65% -68.18% -51.55% Cidara Therapeutics -289.05%-69.64%-33.73% Does the media refer more to ABUS or CDTX? In the previous week, Arbutus Biopharma had 8 more articles in the media than Cidara Therapeutics. MarketBeat recorded 11 mentions for Arbutus Biopharma and 3 mentions for Cidara Therapeutics. Arbutus Biopharma's average media sentiment score of 0.59 beat Cidara Therapeutics' score of 0.47 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cidara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ABUS or CDTX? Arbutus Biopharma currently has a consensus price target of $5.50, suggesting a potential upside of 68.20%. Cidara Therapeutics has a consensus price target of $39.14, suggesting a potential upside of 81.38%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more risk & volatility, ABUS or CDTX? Arbutus Biopharma has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. SummaryCidara Therapeutics beats Arbutus Biopharma on 11 of the 19 factors compared between the two stocks. Remove Ads Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$236.37M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-0.8529.2923.1419.03Price / Sales185.38436.17385.7893.17Price / CashN/A168.6838.1634.64Price / Book-11.863.956.934.33Net Income-$22.93M-$71.95M$3.20B$247.06M7 Day Performance-3.96%-3.76%-2.30%-0.37%1 Month Performance-13.33%-10.33%2.86%-3.85%1 Year Performance17.28%-27.15%10.66%1.27% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.4024 of 5 stars$21.58+3.6%$39.14+81.4%+28.1%$236.37M$1.28M-0.8590Short Interest ↑ABUSArbutus Biopharma1.4613 of 5 stars$3.28-0.6%$5.50+67.7%+25.8%$621.53M$6.74M-7.6390Earnings ReportAnalyst RevisionNews CoverageSANASana Biotechnology3.2117 of 5 stars$2.77-5.5%$12.25+342.2%-81.6%$618.46MN/A-1.98380News CoverageCDXCChromaDex4.4964 of 5 stars$7.94+1.3%$9.03+13.8%N/A$617.34M$99.60M794.79120Analyst ForecastKALVKalVista Pharmaceuticals4.3335 of 5 stars$12.49-0.9%$23.80+90.6%+11.5%$617.23MN/A-3.43100Analyst ForecastNews CoverageMGTXMeiraGTx4.777 of 5 stars$7.87+1.0%$24.50+211.3%+19.0%$615.06M$13.93M-6.50300Analyst RevisionHigh Trading VolumePHARPharming Group2.1525 of 5 stars$8.89-0.7%$30.00+237.5%-20.2%$604.80M$285.75M-34.19280Short Interest ↑ARVNArvinas3.8194 of 5 stars$8.70+3.2%$37.47+330.7%-80.5%$598.32M$263.40M-3.14420Short Interest ↓High Trading VolumeRLAYRelay Therapeutics2.2808 of 5 stars$3.51-4.1%$19.80+464.1%-63.4%$595.02M$10.01M-1.34330IMTXImmatics1.6164 of 5 stars$4.98+9.5%$16.67+234.7%-57.6%$594.39M$115.50M-7.55260News CoverageKURAKura Oncology4.3102 of 5 stars$7.29+2.1%$25.50+249.8%-66.3%$588.70M$53.88M-3.09130Analyst Upgrade Remove Ads Related Companies and Tools Related Companies Arbutus Biopharma Competitors Sana Biotechnology Competitors ChromaDex Competitors KalVista Pharmaceuticals Competitors MeiraGTx Competitors Pharming Group Competitors Arvinas Competitors Relay Therapeutics Competitors Immatics Competitors Kura Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts